Significantly, RAS mutations, usually in KRAS and NRAS, are also frequent events in myeloid malignancies, and have been detected in 3% to 40% of myelodysplastic syndrome (MDS) and AML [5–7]. This evidence concerns the gene NRAS and myeloid neoplasm.